CA 19-9 as a serum marker in urothelial carcinoma

Urology Annals

Volumn 4, Issue 2, 2012, Pages 98-101

  Pall, Mahander ^a   Iqbal, Javid ^a   Singh, Shrawan Kumar ^a   Rana, Satya Vati ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CA19 9; screening; tumor marker; urothelial carcinoma

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER PROGNOSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 84862080059     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.95555     Document Type: Article

References (24)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol 1998;16:17-22.
3. Shelfo SW, Soloway MS. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional cell cancer of the bladder. World J Urol 1997;15:107-11.
4. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancer of urinary tract. Science 1945;101:519-20.
5. Koprowski H, Steplewski Z. Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-71.
6. Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E. A comparison of urinary nuclear matrix protein-22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer: The prognostic value of false-positive results. BJU Int 2001;88:692-701.
7. Ewing R, Tate GM, Hetherington JW. Urinary fibrin/fibrinogen degradation products in transitional cell carcinoma of the bladder. Br J Urol 1987;59:53-8.
8. Koprowski H, Herlyn M. Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53-5.
9. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983;29:549-52.
10. Itkowitz SH, Kim YS. New carbohydrate tumor markers. Gastroenterology 1986;90:491-94.
11. Itkowitz SH, Yuan M, Fukushi Y, Lee H, Shi ZR, Zurawski V Jr, et al. Immunohistochemical comparison of Lea monosialosyl Lea (CA 19-9), and disialosyl Lea antigens in human colorectal and pancreatic tissues. Can Res 1988;48:3834-42.
12. Hirano K, Kawa S, Oguchi H, Kobayashi T, Yonekura H, Ogata H, et al. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA 19-9 levels. J Natl Cancer Inst 1987;791261-8.
13. Tempero MA, Uchida E, Takaski H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen CA 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501-3.
14. Sashide K, Isobe H, Wakumoto Y, Hanazawa K, Fujita K, Fujime M. CA 19-9 as a serum marker for poor prognosis in urothelial carcinoma. Urol Int 2004;72:112-7.
15. Kurokawa K, Kurihara J, Nakata S, Matsuo Y, Ebihara K, Kurihara H, et al. The clinical significance of carbohydrate antigen 19-9 (CA 19-9) in transitional cell cancer of urinary tract. Nippon Hinyokika Gakkai Zasshi 1993;84:1074-81.
16. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
17. Sugaya Y, Ochi M, Hashimoto S, Muraki J, Morita T, Kobayashi Y, et al. A case of transitional cell carcinoma of renal pelvis with extremely high serum level of CA19-9 and CEA. Hinyokika Kiyo 1997;43:495-9.
18. Yamamoto H, Ueda Y, Maruyama T, Kondou N, Nojima M, Takiuchi H, et al. A case of CA 19-9 producing transitional cell carcinoma ureter. Hinyokika Kiyo 2003;49:543-5.
19. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
20. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: A contemporary series. J Urol 2001;165:1111-6.
21. Otto T, Goepel M, Heider KH, Rubben H. Prognostic factors for bladder cancer. Urol Res 1995;23:137-41.
22. Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N, Varthalitis J, et al. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 1996;19:271-7.
23. Hegele A, Mecklenburg V, Varga Z, Olbert P, Hofmann R, Barth P. CA19.9 and CEA in transitional cell carcinoma of the bladder: Serological and immunohistochemical findings. Anticancer Res 2010;30:5195-200.
24. Lynch CF, Cohen MB. Urinary system. Cancer 1995;75:316-29.